CDK12 and cancer: Thus, this study provides the first evidence to our knowledge that CDK12 mutation triggers activation of the cyclic GMP-AMP synthase (cGAS)/STING pathway, a key component of antitumor immunity, and establishes STING activation as the underlying mechanism driving T cell recruitment in cancers with CDK12 mutations.